Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ADVENZYMES vs LIN, SHW, ECL: Buyback Yield % Comparison
For the Specialty Chemicals subindustry, Advanced Enzyme Technologies's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Enzyme Technologies Buyback Yield % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Advanced Enzyme Technologies's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Advanced Enzyme Technologies's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Enzyme Technologies (NSE:ADVENZYMES) has a Buyback Yield % of 0.00 as of Aug. 21, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Advanced Enzyme Technologies and its competitors. According to the industry distribution chart, Advanced Enzyme Technologies ranks #999999 out of 289 companies in the Chemicals industry.
Is Advanced Enzyme Technologies' Buyback Yield % too high?
Advanced Enzyme Technologies' current Buyback Yield % is 0.00. Based on the distribution chart, Advanced Enzyme Technologies ranks #999999 out of 289 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Advanced Enzyme Technologies has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Enzyme Technologies' Buyback Yield % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Advanced Enzyme Technologies ranks #999999 out of 289 companies for Buyback Yield %. This places Advanced Enzyme Technologies in the lower half of its industry. The industry median Buyback Yield % is 0.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Chemicals company?
The median Buyback Yield % among Chemicals companies is 0.03, based on 289 companies in the industry. Companies in the top quartile (top 25%) have a Buyback Yield % significantly above this median, while those in the bottom quartile fall well below. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Advanced Enzyme Technologies and its competitors. For the Chemicals industry, the median Buyback Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Enzyme Technologies's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Enzyme Technologies stock overvalued right now?
Based on GuruFocus' analysis, Advanced Enzyme Technologies (NSE:ADVENZYMES) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹408.75, compared to a current price of ₹303.00 — trading 25.9% below its estimated fair value. The current Buyback Yield % is 0.00. Advanced Enzyme Technologies' overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Advanced Enzyme Technologies (NSE:ADVENZYMES), the current Buyback Yield % is 0.00 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Enzyme Technologies stock appears to be undervalued.
The current stock price of ₹303.00 is trading 25.9% below its estimated GF Value™ of ₹408.75.
GuruFocus considers Advanced Enzyme Technologies to be Modestly Undervalued.
Key valuation signals for NSE:ADVENZYMES:
Buyback Yield %: 0.00
GF Value™: ₹408.75 vs. price of ₹303.00 (25.9% below fair value)
No single metric tells the full story. See the NSE:ADVENZYMES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Enzyme Technologies Ltd is an Indian company engaged in research activities to manufacture and sell enzymes. The company operates only in one business segment, viz., manufacturing and sales of enzymes. The company offers enzymes for human healthcare and nutrition, animal nutrition, food processing, and non-food processing. Some of the products offered by the company are serratiopeptidase, fungal lipase, papain, hemicellulose, and digegrain, among others. Geographically, the entity operates in India, Europe, the USA, Asia, and other countries, of which a majority of the revenue is derived from India.
89GF Score
Get the complete analysis for NSE:ADVENZYMES
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ADVENZYMES has been successfully added to your 
